What the business is
Candid Therapeutics develops T-cell engager antibodies for autoimmune diseases; its lead drug cizutamig targets CD3 and BCMA.
The bet
B-cell-killing T-cell engagers built for cancer will also work in autoimmune disease, so UCB paid for Phase 1 data and a team rather than waiting.
Starting capital
$370M launch financing in 2024, backed by Two River Group and Vida Ventures.
How it started
Candid was founded in 2024 in San Diego with a $370M launch, led by Dr Ken Song, who previously led RayzeBio through its $4.1B sale to Bristol Myers Squibb in late 2023. Its lead drug cizutamig, a bispecific antibody linking a T-cell to a plasma cell, was originally developed for multiple myeloma.
What happened
By May 2026 cizutamig had been evaluated in over 100 patients across myeloma and autoimmune indications and was in Phase 1 studies across more than ten autoimmune diseases. In March 2026 Candid had announced a reverse merger with the listed Rallybio to go public, which The Next Web said the UCB offer appeared to supersede.
How it ended up
On May 3, 2026 UCB announced it would pay $2B upfront plus up to $200M in milestones, with closing expected by the end of Q2 or early Q3 pending antitrust clearance. It was UCB's second T-cell engager bet in months, after licensing Antengene's CD19/CD3 candidate ATG-201 in a deal worth up to $1.1B.
What has to be true
Early human data for T-cell engagers in autoimmune disease were strong enough that pharma priced the modality as if it works.
Immunology is the largest pharmaceutical market after oncology, so the prize for success is very large.
Candid's chief executive had led RayzeBio to a $4.1B sale, so UCB was also buying a proven operator.
A second BCMA-based engager added breadth to UCB's CD19/CD3 licence.
What can be applied
In a hot modality, buyers pay for early data and proven operators; the risk is that one rival's high price sets the market before late-stage data exists.
Aftermath
As of May 4, 2026, UCB had announced the deal and expected it to close by the end of Q2 or early Q3 pending antitrust clearance, and it reaffirmed its 2026 guidance. The Next Web said Phase 2 readouts over the next 18 months would show whether the price proved timely or expensive.
FOLLOW THE EVIDENCE